The US Food and Drug Administration (FDA) has granted approval for Stealth Therapeutics’ Invisiport implantable arm port, intended for use in patients requiring long-term intravenous treatment.
The Invisiport incorporates a patented self-deploying wing that reduces insertion size and improves stability after implantation.
The port provides a less invasive, patient-friendly option to standard chest ports and peripherally inserted central catheters.
Kegonsa Seed Fund and Wisconsin’s premier seed venture capital fund has supported Stealth in FDA submission and commercialisation work.
Share this article
